Naturally, our lives would be much simpler if we could just get one “universal” flu vaccine shot that could protect against most strains for a longer period of time – and now it looks like Vaccitech, a private spinoff of Oxford University in the UK, is getting closer and closer to that goal.

The MVA-NP+M1 vaccine is supposed to work differently than regular influenza vaccines. It’s intended to boost those T-cells – a type of immune cell – that are already familiar with the flu and uses the stable core material of the virus to do so. Unlike the proteins on the surface, in influenza type A (the most common source of infection for us)those core proteins hardly change, making them a potentially great vaccine target.

The world-first trial is currently testing the vaccine’s efficacy in 862 people aged 65 and older, and the researchers are estimating to complete this effort by October 2019.

But no one seems to be asking, nor do they seem to care, what could be in this new vaccine. All we have to go on is the word of the vaccine manufacturer who says this is safe, and wouldn’t profit if they said otherwise.

“If we get positive data that shows we can affect rates of hospitalization and illness with influenza then there is no question in my mind that a partner would take this on,” Vaccitech CEO Tom Evans told Reuters. “This could be a game-changer in a very competitive market,” says Evans, who will profit immensely off of this new vaccine – whether it works and is safe or not.